spacer
home > ebr > Summer 2020
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2020
   
Text
PDF
bullet
Features
Surfacing Missed Opportunities

David Gwyn at Amplexor

There are five areas in which richer, more holistic product information could shine a light into the life science industry’s blind spots and help transform business outcomes
 
view
download pdf
Base Editing and Its Application to Cell and Gene Therapy

Dr Ceri Wiggins at Horizon Discovery

CRISPR-Cas gene editing has been a force to be reckoned with in gene engineering for years, and it doesn’t seem likely this is going to change anytime soon
 
view
download pdf
Nova Biomedical FLEX®2

With over 1,300 employees and manufacturing facilities in Waltham and Billerica, Massachusetts, and Taipei, Taiwan, Nova Biomedical is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US
 
view
download pdf
bullet
Analytical Methods
Risk Management for Analytical Method Development

Madalena R Testas, Daniela B Santos, and José C Menezes at 4Tune Engineering

In the biopharmaceutical industry, analytical methods are among the most critical elements for process monitoring and product release
 
view
download pdf
Beyond Big Data

Joern Klinger at biotx.ai

We can’t always rely on Big Data to be available; therefore, it’s worth suggesting ways of still effectively applying machine learning when that’s the case
 
view
download pdf
Genotoxic Impurities in Drug Products: Review of Nitrosamine Assays

Elodie Barrau, Emmanuel Desmartin, Valentina Paschetta, Davide Tartaglione, Mònica Coll Furest, and Ana Novak at Eurofins

In the past couple of years, the prevalence of nitrosamines in drug substances has made them a hot topic of conversation in the medical industry
 
view
download pdf
bullet
R&D on COVID-19
The Quest for a Cure

David Wilson at Avacta

It's of little doubt that there is a great need for the development of rapid diagnostic tests to tackle the COVID-19 pandemic
 
view
download pdf
Leveraging Health Data to Support Patient Care

Gilles Paubert at Cegedim Health Data

There are some key areas where current real-world data can add immediate value to patients, the healthcare system, and our economies



 
view
download pdf
Would Greater Diversity and Inclusion Improve Innovation?


Stephen Frost at Frost Included

The pharma industry is responsible for great strides in world health, yet it’s undeniable that there are still many more goals to accomplish, and a lack of diversity may be holding it back

 
view
download pdf
A Conversation with an Expert in Drug Development

As the world grapples with the impact of the COVID-19 pandemic, the life science industry and regulators are racing to find an effective treatment. We spoke with Colin Orford, Senior Vice President of Drug Development services at ICON plc about the direction that this work is taking
 
view
download pdf
bullet
Improving Drug Discovery Models
The Promise of Drug Discovery

The past few decades have seen large strides in the medical industry, but there are still many patients suffering with unmet medical needs that could benefit from further innovation, especially in drug discovery. EBR spoke to Dr Craig Fox, CSO at C4X Discovery, to ask about his thoughts on the subject

 
view
download pdf
Microphysiological Systems Emerging as Powerful Tools for Drug Discovery

Dr Audrey Dubourg at CN Bio

A new class of in vitro model is expected to assist drug discovery by providing robust physiologically relevant data at critical stages of R&D
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

ISO 45001: Global occupational safety and health are important to Gerresheimer

Düsseldorf, June 30,2020: The Gerresheimer Group has declared DIN EN ISO 45001 to be the mandatory global standard for all its plants. It replaces thepreviously applicable standard OHSAS 18001in the field of occupational health and safety.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement